|
Clinical Features
|
GSE32960(train)
|
GSE36682(test)
|
P
|
|---|
|
OS
| | | |
|
0
|
117
|
121
|
0.6897
|
|
1
|
39
|
35
|
|
Metastatic
| | | |
|
NO
|
122
|
124
|
0.8897
|
|
YES
|
34
|
32
|
|
Relapse
| | | |
|
NO
|
132
|
136
|
0.6256
|
|
YES
|
24
|
20
|
|
T Stage
| | | |
|
T1
|
30
|
36
|
0.7632
|
|
T2
|
48
|
41
|
|
T3
|
36
|
35
|
|
T4
|
42
|
44
|
|
N Stage
| | | |
|
N0
|
23
|
21
|
0.7131
|
|
N1
|
73
|
75
|
|
N2
|
39
|
33
|
|
N3
|
21
|
27
|
|
Stage
| | | |
|
I
|
5
|
7
|
0.8443
|
|
II
|
45
|
41
|
|
III
|
47
|
44
|
|
IV
|
59
|
64
|
|
Gender
| | | |
|
Male
|
119
|
114
|
0.6025
|
|
Female
|
37
|
42
|
|
Age
| | | |
|
≤ 45
|
78
|
70
|
0.2474
|
|
>45
|
78
|
86
|
|
EBV
| | | |
|
YES
|
150
|
149
|
1
|
|
NO
|
6
|
7
|
|
Radiotherapy interupt
| | | |
|
NO
|
90
|
88
|
0.9089
|
|
YES
|
66
|
68
|
|
Radiotherapy boosting
| | | |
|
NO
|
85
|
78
|
0.4965
|
|
YES
|
71
|
78
|
|
Cocurrent chemotherapy
| | | |
|
NO
|
26
|
18
|
0.2549
|
|
YES
|
130
|
138
|
